Costs of Cutting Weight—An Economic Evaluation of GLP-1 Agonists vs Gastric Bypass
This economic evaluation compares the long-term cost-effectiveness of glucagon-like peptide-1 (GLP-1) receptor agonists vs Roux-en-Y gastric bypass.
Authors
- Andrea D. Coviello (ORCID: https://orcid.org/0000-0003-0244-9787)
- Maggie M. Hodges (ORCID: https://orcid.org/0000-0001-5814-6932)
- Anthony Charles (ORCID: https://orcid.org/0000-0001-7332-4354)
- Pascal Osi Udekwu (ORCID: https://orcid.org/0000-0002-7724-8034)
- Timothy M. Farrell (ORCID: https://orcid.org/0000-0001-9528-2087)
- William Luo (ORCID: https://orcid.org/0000-0002-6458-9868)
- Ursula Adams (ORCID: https://orcid.org/0000-0002-8424-0671)
Institutions
- University of Vermont (US)
- University of North Carolina at Chapel Hill (US)
- WakeMed (US)
Publication Details
- Journal
- JAMA Surgery
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1001/jamasurg.2025.4385
- Primary Topic
- Bariatric Surgery and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00